Mogamulizumab (Anti-CCR4 / CD194)

Ask supplier a question | View on supplier's website

Mogamulizumab (Anti-CCR4 / CD194) is a defucosylated humanized recombinant monoclonal antibody targeting CCR4. Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL). MW:145.5 KD.

Supplier	Selleck Chemicals
Product #	A2568
Sku #	A2568-1mg*25
Pricing	1mg*25, $5070.00

Feedback